Show simple item record

dc.contributor.authorDickey, John B.
dc.contributor.authorAlbert, Elisabeth
dc.contributor.authorBadr, Mai
dc.contributor.authorLaraja, Kristin M.
dc.contributor.authorSena, Laureen M.
dc.contributor.authorGerson, David S.
dc.contributor.authorSaucedo, Jason E.
dc.contributor.authorQureshi, Waqas
dc.contributor.authorAurigemma, Gerard P.
dc.date2022-08-11T08:08:11.000
dc.date.accessioned2022-08-23T15:45:21Z
dc.date.available2022-08-23T15:45:21Z
dc.date.issued2021-09-01
dc.date.submitted2021-09-30
dc.identifier.citation<p>Dickey JB, Albert E, Badr M, Laraja KM, Sena LM, Gerson DS, Saucedo JE, Qureshi W, Aurigemma GP. A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging. 2021 Sep;14(9):1862-1863. doi: 10.1016/j.jcmg.2021.06.003. Epub 2021 Jun 16. PMID: 34246585; PMCID: PMC8219373. <a href="https://doi.org/10.1016/j.jcmg.2021.06.003">Link to article on publisher's site</a></p>
dc.identifier.issn1876-7591 (Linking)
dc.identifier.doi10.1016/j.jcmg.2021.06.003
dc.identifier.pmid34246585
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27508
dc.description.abstractWide availability of the 3 vaccines approved by the U.S. Food and Drug Administration for emergency use against SARS-CoV-2 has led to reports of adverse reactions not seen during clinical trials: We now report a series of patients who developed CMR-proven myocarditis shortly after vaccination.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34246585&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219373/
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectvaccines
dc.subjectmyocarditis
dc.subjectCardiology
dc.subjectCardiovascular Diseases
dc.subjectImmunology and Infectious Disease
dc.subjectInfectious Disease
dc.subjectVirus Diseases
dc.titleA Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2
dc.typeResponse or Comment
dc.source.journaltitleJACC. Cardiovascular imaging
dc.source.volume14
dc.source.issue9
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/308
dc.identifier.contextkey25210845
html.description.abstract<p>Wide availability of the 3 vaccines approved by the U.S. Food and Drug Administration for emergency use against SARS-CoV-2 has led to reports of adverse reactions not seen during clinical trials: We now report a series of patients who developed CMR-proven myocarditis shortly after vaccination.</p>
dc.identifier.submissionpathcovid19/308
dc.contributor.departmentDepartment of Pediatrics, Division of Pediatric Cardiology
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.source.pages1862-1863


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record